Recent Pfizer Press Releases

  • 12/18/14 8:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN). The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in pain reduction. PHN is a type ofmore...
  • 12/16/14 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 27, 2015. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2014 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.more...
  • 12/16/14 8:00 am EST

    New Campaign Encourages Parents to Take a Pledge to Talk to Their Healthcare Provider About Helping to Protect Their Teen or Young Adult from Meningococcal Meningitis

    NEW YORK--(BUSINESS WIRE)--Paralympic®* medalist and world class snowboarder Amy Purdy and her mother, Sheri, have teamed up with Pfizer Inc. (NYSE:PFE) to launch Take Action Against Meningitis to encourage parents to learn more about how they can help protect their teens and young adults from meningococcal meningitis. One type of invasive meningococcal disease, meningococcal meningitis, is a bacterial infection, which causes inflammation of the protectivemore...
  • 12/15/14 6:30 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the publication of the detailed results from PALOMA-1, a randomized Phase 2 study of palbociclib in combination with letrozole versus letrozole alone, in The Lancet Oncology. As previously disclosed, PALOMA-1 achieved its primary endpoint with the combination of palbociclib and letrozole significantly prolonging progression-free survival (PFS) compared with letrozole alone in post-menopausal women withmore...
  • 12/15/14 12:06 pm EST

    Board of Directors Approves Increase in Quarterly Cash Dividend to $0.28 Per Share

    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 28-cent first-quarter 2015 dividend on the company’s common stock, payable March 3, 2015, to shareholders of record at the close of business on February 6, 2015. Pfizer increased the dividend by approximately 8 percent, to 28 cents from 26 cents per share. The first-quarter 2015 cash dividend will be the 305th consecutive quarterly dividend paid by Pfizer. “Themore...
  • 12/15/14 8:00 am EST
    • hGH-CTP in global clinical development for the treatment of pediatric and adult growth hormone deficiency (GHD)
    • hGH-CTP has potential to reduce dosing frequency of human growth hormone to single weekly injection from current standard of daily injection
    • OPKO to receive upfront payment of $295 million and eligible to receive up to an additional $275 million upon achievement of regulatory milestones
    • Upon Pfizer’s commercialization of hGH-CTP, OPKO is eligible to receive royalty and/or profit sharing payments
    • Pfizer to obtain exclusive license to commercialize hGH-CTP globally
    MIAMI and NEW YORK--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by 2 years of age. hGH-CTP has the potential tomore...
  • 12/10/14 9:00 am EST

    Light-Hearted, Informative Video Refreshes ‘The Mother, Daughter Talk’

    NEW YORK--(BUSINESS WIRE)--Nearly one out of every two (45.25%) American women will be menopausal or approaching menopause next year. While most women are aware of menopausal symptoms, such as hot flashes and night sweats, fewer know about a condition that affects one-third of women called postmenopausal vaginal atrophy. Brenda Strong, best known for her roles in “Dallas” and “Desperate Housewives,” is partnering with Pfizer, Inc to urge women to have open and honestmore...
  • 12/9/14 10:30 am EST

    MYLOTARG™ (gemtuzumab ozogamicin) Demonstrates Promising Efficacy Across Multiple Phase 3 Studies in First-Line Acute Myeloid Leukemia (AML)1,2

    Pfizer in Discussions with Regulators on Path Forward for MYLOTARG

    New Long-Term, Follow-Up Data Show Chronic Myeloid Leukemia (CML) Patients Benefit from BOSULIF® (bosutinib) at 4 and 5 years3,4

    Inotuzumab Ozogamicin Shows Activity in Phase 2 Study of Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)5

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). Among the highlights are results from several investigator-led, large, randomized studies evaluating the antibody-drug conjugate (ADC) MYLOTARG (gemtuzumab ozogamicin) in selectmore...
  • 12/8/14 1:30 pm EST

    Data Presented Today at the 56th Annual American Society of Hematology (ASH) Meeting

    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). Among the highlights are results from several investigator-led, large, randomized studies evaluating the antibody-drug conjugate (ADC) MYLOTARG (gemtuzumab ozogamicin) in selectmore...
  • 12/8/14 8:00 am EST

    Signs Collaboration with Spark Therapeutics to Advance Phase 1/2 Adeno-Associated Virus (AAV) Vector Program in Hemophilia B

    Launches Gene Therapy Unit Headed by Michael Linden, Ph.D., Leading Researcher from King's College London

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients. First is an agreement with Spark Therapeutics to develop SPK-FIX, a program incorporating a bio-engineered AAV vector for the potential treatment of Hemophilia B expected to enter Phase 1/2 clinical trials inmore...